We are live on
!
Find out more
B
Braidwell Portfolio holdings
AUM
$2.7B
1-Year Est. Return
88.53%
This Fund
S&P 500
This Quarter
Est. Return
+3.75%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3B
AUM Growth
-$129M
(-4.1%)
Cap. Flow
-$282M
Cap. Flow
% of AUM
-9.39%
Top 10 Holdings %
Top 10 Hldgs %
30.38%
Holding
102
New
28
Increased
19
Reduced
31
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iRhythm Holdings
IRTC
|
+$56.7M |
| 2 |
Guardant Health
GH
|
+$50.2M |
| 3 |
GENB
Generate Biomedicines
GENB
|
+$43.9M |
| 4 |
Monte Rosa Therapeutics
GLUE
|
+$43.2M |
| 5 |
argenx
ARGX
|
+$42.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edgewise Therapeutics
EWTX
|
+$82.6M |
| 2 |
Align Technology
ALGN
|
+$59.5M |
| 3 |
CG Oncology
CGON
|
+$50.2M |
| 4 |
RAPT
RAPT Therapeutics
RAPT
|
+$31.5M |
| 5 |
Legend Biotech
LEGN
|
+$28.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.27% |
| 2 | Miscellaneous | 12.42% |
| 3 | Financials | 0.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Repligen
RGEN
$9.95B
| $5.6M | 0.19% |
47,500
-34,290
| -42% | -$4.79M |
|
77
Harrow
HROW
$1.4B
| $5.52M | 0.18% |
156,419
-138,872
| -47% | -$6.1M |
|
78
Revvity
RVTY
$14.4B
| $4.24M | 0.14% |
+48,400
| New | +$4.79M |
|
79
Celcuity
CELC
$4.33B
| $3.33M | 0.11% |
+29,198
| New | +$3.18M |
|
80
Praxis Precision Medicines
PRAX
$9.63B
| $3.21M | 0.11% |
+9,976
| New | +$3.09M |
|
81
Pulmonx
LUNG
$102M
| $971K | 0.03% |
752,541
| – | – |
|
|
YARW
82
Yarrow Bioscience
YARW
$98.8M
| $547K | 0.02% |
+18,322
| New | +$534K |
|
83
Adaptive Biotechnologies
ADPT
$4.02B
| – | – |
-311,991
| Closed | -$5.07M |
|
|
84
Align Technology
ALGN
$11.2B
| – | – |
-381,004
| Closed | -$59.5M |
|
85
Biogen
BIIB
$32.3B
| – | – |
-115,700
| Closed | -$20.4M |
|
86
Castle Biosciences
CSTL
$1.02B
| – | – |
-177,183
| Closed | -$6.89M |
|
87
Icon
ICLR
$13.1B
| – | – |
-73,370
| Closed | -$13.4M |
|
88
Karyopharm Therapeutics
KPTI
$42.4M
| – | – |
-303,370
| Closed | -$2.23M |
|
|
89
Legend Biotech
LEGN
$3.87B
| – | – |
-1,298,142
| Closed | -$28.2M |
|
|
RAPT
90
DELISTED
RAPT Therapeutics
RAPT
| – | – |
-929,694
| Closed | -$31.5M |
|
91
Relmada Therapeutics
RLMD
$462M
| – | – |
-1,582,257
| Closed | -$7.64M |
|
|
TERN
92
DELISTED
Terns Pharmaceuticals
TERN
| – | – |
-575,321
| Closed | -$23.2M |
|
|
VTYX
93
DELISTED
Ventyx Biosciences
VTYX
| – | – |
-1,920,255
| Closed | -$17.3M |
|
94
Xencor
XNCR
$1.94B
| – | – |
-459,166
| Closed | -$7.03M |
|
|
ORKA
95
Oruka Therapeutics
ORKA
$6.03B
| – | – |
-84,795
| Closed | -$2.57M |
|
|
BLLN
96
BillionToOne Inc
BLLN
$4.4B
| – | – |
-50,000
| Closed | -$4.09M |
|
Similar funds
CWM
M
AG
NIM
GC
BIAS
CCM
ACP
Braidwell's Q1 2026 Portfolio in Review
As of Q1 2026, Braidwell held 102 positions worth $3B, down 4.1% from $3.13B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Braidwell withdrew a net $282M in Q1 2026, closing 14 positions and reducing 31 holdings. Its most notable exit was Align Technology, an estimated $59.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Braidwell opened a new position in Guardant Health worth $46.2M.
- Braidwell's largest Q1 2026 buy was Guardant Health: 499,712 shares worth $46.2M.
- Braidwell added most to iRhythm Holdings in Q1 2026, an estimated $56.7M increase.
- Braidwell's biggest Q1 2026 reduction was Edgewise Therapeutics, cutting an estimated $82.6M.
- Braidwell fully exited Align Technology in Q1 2026, selling an estimated $59.5M.
- Braidwell's ten largest holdings make up 30% of its $3B portfolio in Q1 2026.
- Braidwell opened 28 new positions and closed 14 in Q1 2026.
- Braidwell's portfolio value fell 4.1% quarter-over-quarter to $3B.
Based on Braidwell's 13F filing for Q1 2026, filed 15 May 2026.